Compare Herbalife Nutrition Ltd (HLF) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs GeneDx Holdings Corp — how do they compare? Herbalife Nutrition Ltd trades at $12.23 (market cap $1.27B), while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| HLF | WGS | |
|---|---|---|
Market Cap | $1.27B | $1.80B |
Sector | Consumer Staples | Technology |
52-Week High | $19.96 | $167.51 |
52-Week Low | $7.75 | $34.51 |
Enterprise Value | $3.00B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.25, up 2.17% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations, and raised full-year guidance. Revenue remains stable around $5 billion annually, with a net income margin of 4.66%. Valuation ratios appear attractive with a P/E of 5.26 and P/S of 0.25. Debt-to-asset ratio improved to 71.67% in 2025, reflecting progress in deleveraging.
The outlook is mixed: strong analyst support (57.69% buy ratings) and operational improvements contrast with high debt levels and negative shareholder equity. Key risks include competitive pressures and reliance on international growth. Near-term catalyst is Q2 2026 earnings on August 5, 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
